Hos unge og børn skal den mulige fordel ved Crixivan- behandling vurderes i forhold til den øgede risiko for nefrolitiasis (nyresten).
In adolescents and children, the possible benefit of treatment with Crixivan should be weighed up against the increased risk of developing nephrolithiasis (kidney stones).